BioAge Labs, Inc. (BIOA) Discusses Phase I Results and Development Plans for BGE-102 NLRP3 Inhibitor April 21, 2026 8:00 AM EDT
Company Participants
Chris Patil
Kristen Fortney - Co-Founder, CEO, President, Treasurer, Secretary & Director
Paul Rubin - Chief Medical Officer & Executive VP of Research
Conference Call Participants
Yasmeen Rahimi - Piper Sandler & Co., Research Division
Xiaotong Jia - Jefferies LLC, Research Division
Samantha Semenkow - Citigroup Inc., Research Division
Salveen Richter - Goldman Sachs Group, Inc., Research Division
Jay Olson - Oppenheimer & Co. Inc., Research Division
Joseph Stringer - Needham & Company, LLC, Research Division
Michael Ulz - Morgan Stanley, Research Division
Tsan-Yu Hsieh - William Blair & Company L.L.C., Research Division
Presentation
Operator
Greetings, and welcome to the BioAge Labs Update Call. [Operator Instructions] As a reminder, this conference is being recorded.
I would now like to turn the call over to your host, Chris Patil, Vice President, Media. Thank you. Please go ahead.
Chris Patil
Thank you for joining today's call. I'm Chris Patil, VP, Media at BioAge Labs.
Before we begin, I would like to remind everyone that during this call, we will be making forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on our current beliefs, plans, expectations and assumptions as of today and are subject to risks, uncertainties and other factors that could cause actual results to differ materially from those expressed or implied by such statements. These risks and other factors can be found in our most recent annual report on Form 10-K, quarterly reports on Form 10-Q and other filings we have made with the Securities and Exchange Commission.
We encourage you to review these filings as well as the full forward-looking statements disclaimer on Slide 2 for a more complete understanding of the
此内容由惯性聚合(RSS阅读器)自动聚合整理，仅供阅读参考。 原文来自 — 版权归原作者所有。